Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Infection|May 20, 2015
Ageing with HIV: a multidisciplinary reviewA Calcagno, S Nozza, C Muss, et al.
Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.
International Journal of STD & AIDS|August 24, 2013
Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trialI S Gorfinkel, F Aoki, S McNeil, et al.
The Journal of Infectious Diseases|July 1, 1997
Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trialS D Shafran, S L Sacks, F Y Aoki, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.
Infection|July 7, 2014
Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)R Bruno, G Carosi, N Coppola, et al.
The Journal of Infectious Diseases|January 7, 1998
Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study GroupS D Shafran, J Singer, D P Zarowny, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.
BMC Geriatrics|April 22, 2018
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 yearsG Guaraldi, A Malagoli, A Calcagno, et al.
Journal of Viral Hepatitis|August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)S D Shafran, D Shaw, M Charafeddine, et al.
Pageof 15